p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
- PMID: 12951578
- DOI: 10.1038/nrd1177
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Abstract
The p38 MAP kinases are a family of serine/threonine protein kinases that play important roles in cellular responses to external stress signals. Since their identification about 10 years ago, much has been learned of the activation and regulation of the p38 MAP kinase pathways. Inhibitors of two members of the p38 family have been shown to have anti-inflammatory effects in preclinical disease models, primarily through the inhibition of the expression of inflammatory mediators. Several promising compounds have also progressed to clinical trials. In this review, we provide an overview of the role of p38 MAP kinases in stress-activated pathways and the progress towards clinical development of p38 MAP kinase inhibitors in the treatment of inflammatory diseases.
Similar articles
-
The p38 MAP kinase pathway as a therapeutic target in inflammatory disease.Curr Opin Pharmacol. 2004 Aug;4(4):372-7. doi: 10.1016/j.coph.2004.03.009. Curr Opin Pharmacol. 2004. PMID: 15251131 Review.
-
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer.Expert Opin Investig Drugs. 2009 Dec;18(12):1893-905. doi: 10.1517/13543780903321490. Expert Opin Investig Drugs. 2009. PMID: 19852565 Review.
-
MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target.Anat Rec (Hoboken). 2009 Dec;292(12):1902-13. doi: 10.1002/ar.21047. Anat Rec (Hoboken). 2009. PMID: 19943344 Review.
-
Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases.J Cell Physiol. 2003 Dec;197(3):326-35. doi: 10.1002/jcp.10393. J Cell Physiol. 2003. PMID: 14566962
-
Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.J Pharmacol Exp Ther. 2009 Dec;331(3):882-95. doi: 10.1124/jpet.109.158329. Epub 2009 Aug 31. J Pharmacol Exp Ther. 2009. PMID: 19720877 Clinical Trial.
Cited by
-
GSK3179106 ameliorates lipopolysaccharide-induced inflammation and acute lung injury by targeting P38 MAPK.Respir Res. 2024 Oct 28;25(1):388. doi: 10.1186/s12931-024-03012-9. Respir Res. 2024. PMID: 39468539 Free PMC article.
-
Intervention of electroacupuncture on spinal p38 MAPK/ATF-2/VR-1 pathway in treating inflammatory pain induced by CFA in rats.Mol Pain. 2013 Mar 22;9:13. doi: 10.1186/1744-8069-9-13. Mol Pain. 2013. PMID: 23517865 Free PMC article.
-
Regulation of the Mammalian SWI/SNF Family of Chromatin Remodeling Enzymes by Phosphorylation during Myogenesis.Biology (Basel). 2020 Jul 3;9(7):152. doi: 10.3390/biology9070152. Biology (Basel). 2020. PMID: 32635263 Free PMC article. Review.
-
Drugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birth.Front Immunol. 2015 Apr 20;6:166. doi: 10.3389/fimmu.2015.00166. eCollection 2015. Front Immunol. 2015. PMID: 25941525 Free PMC article. Review.
-
p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells.J Neurooncol. 2012 Aug;109(1):35-44. doi: 10.1007/s11060-012-0875-7. Epub 2012 Apr 19. J Neurooncol. 2012. PMID: 22528800
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
